1 | weighted | 4,191 |
2 | geometric | 2,076 |
3 | arithmetic | 294 |
4 | least-squares | 252 |
5 | grand | 136 |
6 | time-weighted | 78 |
7 | complier | 41 |
8 | least-square | 40 |
9 | perimetric | 26 |
10 | unstandardized | 26 |
11 | variance-weighted | 26 |
12 | hodges-lehmann | 15 |
13 | trnase | 14 |
14 | bias-adjusted | 9 |
15 | multirater | 8 |
16 | treatment-arm | 8 |
17 | arcsine | 7 |
18 | importin | 7 |
19 | prevalence-adjusted | 7 |
20 | pooled-effect | 6 |
21 | population-weighted | 6 |
22 | mean± | 5 |
23 | patient-weighted | 5 |
24 | catheterization-determined | 4 |
25 | transstenotic | 4 |
26 | 6-μm | 3 |
27 | antilog | 3 |
28 | evan-g | 3 |
29 | fleiss-cohen | 3 |
30 | sauter | 3 |
31 | sc-weighted | 3 |
32 | two-interval | 3 |
33 | unstandardised | 3 |
34 | volume-weighted | 3 |
35 | adjusted-geometric | 2 |
36 | btsd | 2 |
37 | creatinine-standardized | 2 |
38 | disorders-iv-tr | 2 |
39 | duration-adjusted | 2 |
40 | equanox-3 | 2 |
41 | first-forbidden | 2 |
42 | fixed-marginal | 2 |
43 | goutallier | 2 |
44 | issmi | 2 |
45 | joachim | 2 |
46 | kt/vurea | 2 |
47 | mean+2 | 2 |
48 | menicon | 2 |
49 | multiple-rater | 2 |
50 | mwt-early | 2 |
51 | neo-aristotelian | 2 |
52 | ooas | 2 |
53 | ooks | 2 |
54 | postirrigation | 2 |
55 | standarised | 2 |
56 | stick-slip | 2 |
57 | tagsnp | 2 |
58 | treatment-group-specific | 2 |
59 | 'bujockjung'which | 1 |
60 | 'complier | 1 |
61 | 'heasobyun'which | 1 |
62 | 'recalled | 1 |
63 | .intraoperative | 1 |
64 | 0.33-mm | 1 |
65 | 0.6-1.scm.the | 1 |
66 | 1.51±0.34 | 1 |
67 | 10,359-a | 1 |
68 | 100-mw | 1 |
69 | 102,377 | 1 |
70 | 14-3-3/cav | 1 |
71 | 18.4-hour | 1 |
72 | 2,3,5,4'-tetrahydroxystilbene-2-o- | 1 |
73 | 2-me-3,4-dh | 1 |
74 | 24-h/daytime/nighttime | 1 |
75 | 28-city | 1 |
76 | 3.5-point | 1 |
77 | 4.4±1.9 | 1 |
78 | 5.9-year | 1 |
79 | 6-walk | 1 |
80 | 6.3±1.6 | 1 |
81 | 7.the | 1 |
82 | 72-region | 1 |
83 | 8-13-fold | 1 |
84 | a1c-derived | 1 |
85 | age-normalized | 1 |
86 | anchor.the | 1 |
87 | ancova-adjusted | 1 |
88 | anesthesia.the | 1 |
89 | angular-sampled | 1 |
90 | anteiso-and | 1 |
91 | aortic-root-diameter | 1 |
92 | aortic-to-femoral | 1 |
93 | area-weighted | 1 |
94 | benzoxazolone | 1 |
95 | bioequivalence.the | 1 |
96 | biomechenopharmacological | 1 |
97 | birth-weight-adjusted | 1 |
98 | bp-night-time | 1 |
99 | car-mediated | 1 |
100 | centre/luminescent | 1 |
101 | cobalt-an | 1 |
102 | cobicistat/emtricitabine/tenofovir | 1 |
103 | concentrations/geometric | 1 |
104 | cywee | 1 |
105 | design-adjusted | 1 |
106 | dissection.the | 1 |
107 | dsc=1 | 1 |
108 | e/a-weighted | 1 |
109 | ef-weighted | 1 |
110 | end-of-ebt | 1 |
111 | equanox-4 | 1 |
112 | ffq-estimated | 1 |
113 | filtered-x | 1 |
114 | flexion.the | 1 |
115 | four-sites | 1 |
116 | free-marginal | 1 |
117 | friedman-nemenyi | 1 |
118 | fungi-derived | 1 |
119 | gene-variant | 1 |
120 | homogeneous.the | 1 |
121 | iiq/udi | 1 |
122 | index/transaortic | 1 |
123 | item-adjusted | 1 |
124 | item-wise | 1 |
125 | khadjesari | 1 |
126 | last-4-hour | 1 |
127 | last-6-hour | 1 |
128 | lecithin/butanol/isopropyl | 1 |
129 | literatures.weighted | 1 |
130 | lowest/highest | 1 |
131 | market-weighted | 1 |
132 | mean+/-2 | 1 |
133 | method.. | 1 |
134 | mg/dl.the | 1 |
135 | microperimeter-determined | 1 |
136 | moloi | 1 |
137 | multisubject | 1 |
138 | n-deo/oxybutynin | 1 |
139 | npo-ipo | 1 |
140 | o=c-c=c-n | 1 |
141 | partnership-and | 1 |
142 | patients-whose | 1 |
143 | pblc | 1 |
144 | pd* | 1 |
145 | peak/stance | 1 |
146 | placebo-minus-drug | 1 |
147 | positive-this | 1 |
148 | post-nmm | 1 |
149 | practices’ | 1 |
150 | praziquantelon | 1 |
151 | pre-alt | 1 |
152 | pre-tace | 1 |
153 | province-matched | 1 |
154 | pulmonary-aortic | 1 |
155 | real-valued | 1 |
156 | recidivity | 1 |
157 | rhythm-adjusted | 1 |
158 | rotahaler/diskus | 1 |
159 | s2-g | 1 |
160 | sample-weighted | 1 |
161 | scattered-vessel | 1 |
162 | simkania | 1 |
163 | solution-a | 1 |
164 | spearmańs | 1 |
165 | standradised | 1 |
166 | statins-the | 1 |
167 | steroid/long-acting | 1 |
168 | tc-adjusted | 1 |
169 | therapy.-the | 1 |
170 | three-beat | 1 |
171 | tooth-based | 1 |
172 | trial/control | 1 |
173 | twenty-four-h | 1 |
174 | twenty-four–hour | 1 |
175 | u-enac- | 1 |
176 | uc-adjusted | 1 |
177 | uti.the | 1 |
178 | visitwise | 1 |
179 | vldl/chylomicron | 1 |
180 | wald-wolfkowitz | 1 |
181 | week-one | 1 |
182 | weight-for-length/height | 1 |
183 | weighted/standardized | 1 |
184 | welfare-friendly | 1 |
185 | wnt/ | 1 |
186 | zwittergent | 1 |
187 | |standardised | 1 |
188 | £106.16 | 1 |
189 | ∼3.14-μm | 1 |
1 | 'bujockjung'which | 1 |
2 | 'complier | 1 |
3 | 'heasobyun'which | 1 |
4 | 'recalled | 1 |
5 | .intraoperative | 1 |
6 | 0.33-mm | 1 |
7 | 0.6-1.scm.the | 1 |
8 | 1.51±0.34 | 1 |
9 | 10,359-a | 1 |
10 | 100-mw | 1 |
11 | 102,377 | 1 |
12 | 14-3-3/cav | 1 |
13 | 18.4-hour | 1 |
14 | 2,3,5,4'-tetrahydroxystilbene-2-o- | 1 |
15 | 2-me-3,4-dh | 1 |
16 | 24-h/daytime/nighttime | 1 |
17 | 28-city | 1 |
18 | 3.5-point | 1 |
19 | 4.4±1.9 | 1 |
20 | 5.9-year | 1 |
21 | 6-walk | 1 |
22 | 6-μm | 3 |
23 | 6.3±1.6 | 1 |
24 | 7.the | 1 |
25 | 72-region | 1 |
26 | 8-13-fold | 1 |
27 | a1c-derived | 1 |
28 | adjusted-geometric | 2 |
29 | age-normalized | 1 |
30 | anchor.the | 1 |
31 | ancova-adjusted | 1 |
32 | anesthesia.the | 1 |
33 | angular-sampled | 1 |
34 | anteiso-and | 1 |
35 | antilog | 3 |
36 | aortic-root-diameter | 1 |
37 | aortic-to-femoral | 1 |
38 | arcsine | 7 |
39 | area-weighted | 1 |
40 | arithmetic | 294 |
41 | benzoxazolone | 1 |
42 | bias-adjusted | 9 |
43 | bioequivalence.the | 1 |
44 | biomechenopharmacological | 1 |
45 | birth-weight-adjusted | 1 |
46 | bp-night-time | 1 |
47 | btsd | 2 |
48 | car-mediated | 1 |
49 | catheterization-determined | 4 |
50 | centre/luminescent | 1 |
51 | cobalt-an | 1 |
52 | cobicistat/emtricitabine/tenofovir | 1 |
53 | complier | 41 |
54 | concentrations/geometric | 1 |
55 | creatinine-standardized | 2 |
56 | cywee | 1 |
57 | design-adjusted | 1 |
58 | disorders-iv-tr | 2 |
59 | dissection.the | 1 |
60 | dsc=1 | 1 |
61 | duration-adjusted | 2 |
62 | e/a-weighted | 1 |
63 | ef-weighted | 1 |
64 | end-of-ebt | 1 |
65 | equanox-3 | 2 |
66 | equanox-4 | 1 |
67 | evan-g | 3 |
68 | ffq-estimated | 1 |
69 | filtered-x | 1 |
70 | first-forbidden | 2 |
71 | fixed-marginal | 2 |
72 | fleiss-cohen | 3 |
73 | flexion.the | 1 |
74 | four-sites | 1 |
75 | free-marginal | 1 |
76 | friedman-nemenyi | 1 |
77 | fungi-derived | 1 |
78 | gene-variant | 1 |
79 | geometric | 2,076 |
80 | goutallier | 2 |
81 | grand | 136 |
82 | hodges-lehmann | 15 |
83 | homogeneous.the | 1 |
84 | iiq/udi | 1 |
85 | importin | 7 |
86 | index/transaortic | 1 |
87 | issmi | 2 |
88 | item-adjusted | 1 |
89 | item-wise | 1 |
90 | joachim | 2 |
91 | khadjesari | 1 |
92 | kt/vurea | 2 |
93 | last-4-hour | 1 |
94 | last-6-hour | 1 |
95 | least-square | 40 |
96 | least-squares | 252 |
97 | lecithin/butanol/isopropyl | 1 |
98 | literatures.weighted | 1 |
99 | lowest/highest | 1 |
100 | market-weighted | 1 |
101 | mean+/-2 | 1 |
102 | mean+2 | 2 |
103 | mean± | 5 |
104 | menicon | 2 |
105 | method.. | 1 |
106 | mg/dl.the | 1 |
107 | microperimeter-determined | 1 |
108 | moloi | 1 |
109 | multiple-rater | 2 |
110 | multirater | 8 |
111 | multisubject | 1 |
112 | mwt-early | 2 |
113 | n-deo/oxybutynin | 1 |
114 | neo-aristotelian | 2 |
115 | npo-ipo | 1 |
116 | o=c-c=c-n | 1 |
117 | ooas | 2 |
118 | ooks | 2 |
119 | partnership-and | 1 |
120 | patient-weighted | 5 |
121 | patients-whose | 1 |
122 | pblc | 1 |
123 | pd* | 1 |
124 | peak/stance | 1 |
125 | perimetric | 26 |
126 | placebo-minus-drug | 1 |
127 | pooled-effect | 6 |
128 | population-weighted | 6 |
129 | positive-this | 1 |
130 | post-nmm | 1 |
131 | postirrigation | 2 |
132 | practices’ | 1 |
133 | praziquantelon | 1 |
134 | pre-alt | 1 |
135 | pre-tace | 1 |
136 | prevalence-adjusted | 7 |
137 | province-matched | 1 |
138 | pulmonary-aortic | 1 |
139 | real-valued | 1 |
140 | recidivity | 1 |
141 | rhythm-adjusted | 1 |
142 | rotahaler/diskus | 1 |
143 | s2-g | 1 |
144 | sample-weighted | 1 |
145 | sauter | 3 |
146 | sc-weighted | 3 |
147 | scattered-vessel | 1 |
148 | simkania | 1 |
149 | solution-a | 1 |
150 | spearmańs | 1 |
151 | standarised | 2 |
152 | standradised | 1 |
153 | statins-the | 1 |
154 | steroid/long-acting | 1 |
155 | stick-slip | 2 |
156 | tagsnp | 2 |
157 | tc-adjusted | 1 |
158 | therapy.-the | 1 |
159 | three-beat | 1 |
160 | time-weighted | 78 |
161 | tooth-based | 1 |
162 | transstenotic | 4 |
163 | treatment-arm | 8 |
164 | treatment-group-specific | 2 |
165 | trial/control | 1 |
166 | trnase | 14 |
167 | twenty-four-h | 1 |
168 | twenty-four–hour | 1 |
169 | two-interval | 3 |
170 | u-enac- | 1 |
171 | uc-adjusted | 1 |
172 | unstandardised | 3 |
173 | unstandardized | 26 |
174 | uti.the | 1 |
175 | variance-weighted | 26 |
176 | visitwise | 1 |
177 | vldl/chylomicron | 1 |
178 | volume-weighted | 3 |
179 | wald-wolfkowitz | 1 |
180 | week-one | 1 |
181 | weight-for-length/height | 1 |
182 | weighted | 4,191 |
183 | weighted/standardized | 1 |
184 | welfare-friendly | 1 |
185 | wnt/ | 1 |
186 | zwittergent | 1 |
187 | |standardised | 1 |
188 | £106.16 | 1 |
189 | ∼3.14-μm | 1 |
1 | pd* | 1 |
2 | u-enac- | 1 |
3 | 2,3,5,4'-tetrahydroxystilbene-2-o- | 1 |
4 | method.. | 1 |
5 | wnt/ | 1 |
6 | dsc=1 | 1 |
7 | mean+2 | 2 |
8 | mean+/-2 | 1 |
9 | equanox-3 | 2 |
10 | equanox-4 | 1 |
11 | 1.51±0.34 | 1 |
12 | 6.3±1.6 | 1 |
13 | £106.16 | 1 |
14 | 102,377 | 1 |
15 | 4.4±1.9 | 1 |
16 | 10,359-a | 1 |
17 | solution-a | 1 |
18 | kt/vurea | 2 |
19 | simkania | 1 |
20 | treatment-group-specific | 2 |
21 | perimetric | 26 |
22 | geometric | 2,076 |
23 | adjusted-geometric | 2 |
24 | concentrations/geometric | 1 |
25 | arithmetic | 294 |
26 | transstenotic | 4 |
27 | pulmonary-aortic | 1 |
28 | index/transaortic | 1 |
29 | pblc | 1 |
30 | province-matched | 1 |
31 | 'recalled | 1 |
32 | angular-sampled | 1 |
33 | catheterization-determined | 4 |
34 | microperimeter-determined | 1 |
35 | tooth-based | 1 |
36 | standradised | 1 |
37 | unstandardised | 3 |
38 | |standardised | 1 |
39 | standarised | 2 |
40 | car-mediated | 1 |
41 | ffq-estimated | 1 |
42 | weighted | 4,191 |
43 | e/a-weighted | 1 |
44 | area-weighted | 1 |
45 | sc-weighted | 3 |
46 | variance-weighted | 26 |
47 | sample-weighted | 1 |
48 | time-weighted | 78 |
49 | volume-weighted | 3 |
50 | ef-weighted | 1 |
51 | population-weighted | 6 |
52 | market-weighted | 1 |
53 | patient-weighted | 5 |
54 | literatures.weighted | 1 |
55 | ancova-adjusted | 1 |
56 | tc-adjusted | 1 |
57 | uc-adjusted | 1 |
58 | prevalence-adjusted | 7 |
59 | item-adjusted | 1 |
60 | rhythm-adjusted | 1 |
61 | design-adjusted | 1 |
62 | duration-adjusted | 2 |
63 | bias-adjusted | 9 |
64 | birth-weight-adjusted | 1 |
65 | real-valued | 1 |
66 | a1c-derived | 1 |
67 | fungi-derived | 1 |
68 | creatinine-standardized | 2 |
69 | weighted/standardized | 1 |
70 | unstandardized | 26 |
71 | age-normalized | 1 |
72 | 8-13-fold | 1 |
73 | anteiso-and | 1 |
74 | partnership-and | 1 |
75 | grand | 136 |
76 | btsd | 2 |
77 | pre-tace | 1 |
78 | peak/stance | 1 |
79 | cywee | 1 |
80 | therapy.-the | 1 |
81 | statins-the | 1 |
82 | 7.the | 1 |
83 | anesthesia.the | 1 |
84 | bioequivalence.the | 1 |
85 | uti.the | 1 |
86 | mg/dl.the | 1 |
87 | 0.6-1.scm.the | 1 |
88 | dissection.the | 1 |
89 | flexion.the | 1 |
90 | anchor.the | 1 |
91 | homogeneous.the | 1 |
92 | bp-night-time | 1 |
93 | 24-h/daytime/nighttime | 1 |
94 | arcsine | 7 |
95 | week-one | 1 |
96 | benzoxazolone | 1 |
97 | least-square | 40 |
98 | trnase | 14 |
99 | item-wise | 1 |
100 | visitwise | 1 |
101 | patients-whose | 1 |
102 | .intraoperative | 1 |
103 | s2-g | 1 |
104 | evan-g | 3 |
105 | steroid/long-acting | 1 |
106 | antilog | 3 |
107 | placebo-minus-drug | 1 |
108 | twenty-four-h | 1 |
109 | 'bujockjung'which | 1 |
110 | 'heasobyun'which | 1 |
111 | 2-me-3,4-dh | 1 |
112 | iiq/udi | 1 |
113 | issmi | 2 |
114 | moloi | 1 |
115 | khadjesari | 1 |
116 | friedman-nemenyi | 1 |
117 | 6-walk | 1 |
118 | biomechenopharmacological | 1 |
119 | fixed-marginal | 2 |
120 | free-marginal | 1 |
121 | aortic-to-femoral | 1 |
122 | two-interval | 3 |
123 | scattered-vessel | 1 |
124 | trial/control | 1 |
125 | lecithin/butanol/isopropyl | 1 |
126 | joachim | 2 |
127 | 0.33-mm | 1 |
128 | post-nmm | 1 |
129 | treatment-arm | 8 |
130 | ∼3.14-μm | 1 |
131 | 6-μm | 3 |
132 | o=c-c=c-n | 1 |
133 | cobalt-an | 1 |
134 | neo-aristotelian | 2 |
135 | first-forbidden | 2 |
136 | fleiss-cohen | 3 |
137 | n-deo/oxybutynin | 1 |
138 | importin | 7 |
139 | hodges-lehmann | 15 |
140 | menicon | 2 |
141 | 72-region | 1 |
142 | postirrigation | 2 |
143 | praziquantelon | 1 |
144 | vldl/chylomicron | 1 |
145 | npo-ipo | 1 |
146 | stick-slip | 2 |
147 | tagsnp | 2 |
148 | 5.9-year | 1 |
149 | goutallier | 2 |
150 | complier | 41 |
151 | 'complier | 1 |
152 | multiple-rater | 2 |
153 | multirater | 8 |
154 | aortic-root-diameter | 1 |
155 | sauter | 3 |
156 | cobicistat/emtricitabine/tenofovir | 1 |
157 | disorders-iv-tr | 2 |
158 | last-4-hour | 1 |
159 | 18.4-hour | 1 |
160 | last-6-hour | 1 |
161 | twenty-four–hour | 1 |
162 | ooas | 2 |
163 | least-squares | 252 |
164 | four-sites | 1 |
165 | positive-this | 1 |
166 | ooks | 2 |
167 | rotahaler/diskus | 1 |
168 | spearmańs | 1 |
169 | three-beat | 1 |
170 | end-of-ebt | 1 |
171 | pooled-effect | 6 |
172 | multisubject | 1 |
173 | weight-for-length/height | 1 |
174 | pre-alt | 1 |
175 | gene-variant | 1 |
176 | centre/luminescent | 1 |
177 | zwittergent | 1 |
178 | 3.5-point | 1 |
179 | lowest/highest | 1 |
180 | 14-3-3/cav | 1 |
181 | 100-mw | 1 |
182 | filtered-x | 1 |
183 | welfare-friendly | 1 |
184 | mwt-early | 2 |
185 | 28-city | 1 |
186 | recidivity | 1 |
187 | wald-wolfkowitz | 1 |
188 | practices’ | 1 |
189 | mean± | 5 |